Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Tax loss selling!! Happens every November. And if people with large holdings made money elsewhere and don’t think Billy Boy will deliver with something unbelievable, then who knows how low this will go!
One day doesn’t compare to VZ trading over 15 million plus a day in share volume!!!! Your simply down right and incredibly wrong if trying to make the same comparison!!!
And I should have said over $700 MILLION!
That’s insane to compare something that traded over $100 million in share volume to something that didn’t. Apples and Ants!
VZ traded 20 million shares at an average price of $36. Are you really comparing Apples and Ants???
Friday sell off as usual with a touch of Capitulation possibly ahead….
Who got caught in the Gap & Trap yesterday? Not me. But maybe you!
Oh look, heading back to the $.40’s today it seems…..
It’s Low Volume Mr. Keyboard warrior.
Hence my Gap & Trap comment for the poor souls that bought on the upswing yesterday with again - Low Volume
Until an actual announcement of a collaboration is 8K’d / PR’d, this has no parachute to stop the free fall back down…
See everyone back at $.44 next week.
I should have said 8K’d. Yes no PR, but filing was issued yesterday.
Between the Gap created yesterday and the Tax Loss Harvesting selling that has begun, this will be back to the $.40’s range in my opinion.
What figure was the Gap at??? Whys it not continuing going up on the low volume pump from yesterday if it was not the typical Gap up after a fluff pr huh???
That happened yesterday….
With Tax Loss selling happening and beginning since Mid- October, I’m guessing there are a lot of Shareholders screaming at the CEO to help stop the bleed with a PR…..
Looks to be a typical “Gap & Trap” this morning setting up with the small purchase at $.54
That along with the corrupt (in my opinion) CEO who probably is shorting the stock like he did with SCLX
That’s a big fat negative…. More like Tax Loss selling.
Yeah, no one wants to be without shares when the Dr drops the “Mutha of all PR’s”..
And in the case of IPIX like it is here with Galera, the FDA constantly wants more testing and more testing. But yet for an experimental MRNA shot which scientists and the medical community will not truly know the effects for another 5 years on one’s health, they green light. In my opinion, it’s all about who greases whose palms!!!
Overreaction??? This looks to be going down the route of IPIX. Both of these companies Galera and Innovation Pharma had a product for OM and both of them have been rejected by the FDA. It’s amazing to me the stupidity of how it goes especially since they have nothing that really works right now and patients that develop OM usually have to stop cancer treatments and then decide whether or not to continue once the symptoms subside and heal. And the cost for a severe OM patient to be treated is very, very expensive.
Not bad??? Check out market reaction. Down 50% pre market.
Doesn’t anyone read Filings anymore on companies or do they just read message boards and believe everything that everyone says on it????
Item 4.01
Changes in Registrant’s Certifying Accountant.
On October 29, 2023, the Audit Committee of the Board of Directors of Innovation Pharmaceuticals Inc. (the “Company”) dismissed Pinnacle Accountancy Group of Utah (a d/b/a of Heaton & Company, PLLC) (“Pinnacle”) as the Company’s independent public accounting firm, a role Pinnacle held since 2018. Also on October 29, 2023, the Audit Committee approved the engagement of GreenGrowth CPAs (“GreenGrowth”) as the Company’s new independent public accounting firm, and the Company engaged GreenGrowth in such capacity. The Audit Committee approved the transition following the sale of a portion of Pinnacle’s public company accounting practice to GreenGrowth.
The reports of Pinnacle on the Company’s financial statements for the fiscal years ended June 30, 2023 and June 30, 2022 did not contain an adverse opinion or a disclaimer of opinion, and were not qualified or modified as to uncertainty, audit scope or accounting principles, other than an explanatory paragraph relating to the Company’s ability to continue as a going concern in each report based on the Company’s negative working capital, losses and negative cash flow.
During the fiscal years ended June 30, 2023 and June 30, 2022 and during the subsequent interim period through October 29, 2023, there were no disagreements within the meaning of Item 304(a)(1)(iv) of Regulation S-K between the Company and Pinnacle on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which disagreements, if not resolved to Pinnacle’s satisfaction, would have caused Pinnacle to make reference thereto in their reports. During the fiscal years ended June 30, 2023 and June 30, 2022 and during the subsequent interim period through October 29, 2023, there were no reportable events within the meaning of Item 304(a)(1)(v) of Regulation S-K, except that, as initially reported in Part II, Item 9A of the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2023, the Company reported a material weakness in its internal control over financial reporting during such period related to the Company’s accounting procedures relevant to an unconsolidated foreign investment being insufficiently formal.
The Company provided Pinnacle with a copy of the disclosure it is making herein in response to Item 304(a) of Regulation S-K, and requested Pinnacle furnish the Company with a copy of its letter addressed to the Securities and Exchange Commission, pursuant to Item 304(a)(3) of Regulation S-K, stating whether or not Pinnacle agrees with the statements related to them made by the Company in this report. A copy of Pinnacle’s letter dated October 30, 2023 is attached as Exhibit 16.1 to this report.
During the fiscal years ended June 30, 2023 and June 30, 2022 and during the subsequent interim period through October 29, 2023, neither the Company nor anyone on its behalf has consulted with GreenGrowth regarding: (i) the application of accounting principles to a specific transaction, either completed or proposed, or the type of audit opinion that might be rendered on the Company’s financial statements, and neither a written report nor oral advice was provided to the Company that GreenGrowth concluded was an important factor considered by the Company in reaching a decision as to any accounting, auditing, or financial reporting issue; (ii) any matter that was the subject of a disagreement within the meaning of Item 304(a)(1)(iv) of Regulation S-K and the related instructions; or (iii) any reportable event within the meaning of Item 304(a)(1)(v) of Regulation S-K.
8K announcement about CPA change….
Well if you think of it as in proportion to what IPIX share price was before the Clinical Trial of Brilacidin happened for CV-19, seems on point. Same 93 - 95% share price take down by Market Makers. Is it called for??? Only they can say.
You would have thought that would have been the case. The safest medication to date I believe would be the swish, gargle and spit form that IPIX has but unfortunately cannot afford to progress to Phase 3.
Well looks like the FDA did a # on Galera like they did with IPIX and the shareholders have seen the stock dip from the almost $4.00 a share range to under $.20 now. So if anyone thinks it’s takeover for IPIX, just look at the entire Pharma industry as a whole.
Hopefully the Dr picked a CPA firm and has that ball rolling. If so, by years end I’m hoping. Start 2024 with a blast!
Strap in…. Take Off will be Fast & Furious..
Calling all Stonk luverz……. Where be it the Rocket Fuel….. Take Off Imminent.
I see a $.25+ once fins are updated and OTCQB Uplist happens.
To me it seems the shares are in very strong hands and the MM’s are not willing to risk selling the shares short and getting surprised by an Otiko bonanza PR…. Just my opinion.
Well the FDA seems to overstep sometimes under the veil of “in the interest of humanity”, but it is more in my opinion under the veil of “Hoe much you paying me to approve” since Big Pharma has all these individuals in their pockets. Prime example is how the Merck COViD 19 drug got approved when they purchased it over from Ridgeback.
$1.00 could be the baseline if and when the Dr finally starts posting the financials and Uplists to the OTCQB. But he definitely needs to start being more informative to shareholders and not think shareholders will accept once every couple of months of PR’s which come off as fluff without follow through. Just my opinion and I’ve been a longtime shareholder with millions of shares for years.
Regen BioPharma, Inc. Expects Second Phase of Confirmatory Study Shortly
SAN DIEGO, Oct. 18, 2023 PRNewswire
Regen BioPharma, Inc. (OTC-PINK: RGBP) (OTC-PINK: RGBPP) is currently developing a genetic approach to regulating NR2F6 levels in human T cells. The Company has recently received unexpected and potentially extremely useful data from one of its contract research organizations (CRO) retained to perform experimental studies on the Company's DuraCAR CAR T-cell therapeutic. These studies demonstrated that T cells which express the chimeric antigen receptor (CAR) construct expressing siRNA for NR2F6 can be successfully created.
"A second unrelated CRO is currently performing qRT-PCR tests to determine if NR2F6 mRNA is elevated or inhibited by our CAR in T-Cells," says Dr. Harry Lander, Chief Scientific Consultant to the Company." If NR2F6 mRNA is suppressed (stimulating certain immune functions) then this product shows potential for treatment of cancer and if NR2F6 mRNA is elevated (suppressing certain immune functions) then the product shows potential for treatment of autoimmune disorders."
Once the Company receives the data, it will analyze the results and report the findings in a press release in order to keep the company's shareholders informed of its progress.
"We know our shareholders are anxious to hear about our results surrounding modifying NR2F6 levels in CAR T-cells and we will get this data out as soon as we can," says Dr. David Koos, Chairman and CEO of the company.
For me it’s always been about what we show as Q4 results since I expected them to be financially sound and flush with cash by end of Q4. Just my opinion.